Climb Bio Presents CLYM116 Phase 1 Safety Data; Data Support Continued Development

What happened

Climb Bio presented initial Phase 1 safety data and translational modeling results for CLYM116 at the European Renal Association Congress. The data showed a favorable safety profile, supporting continued development of the anti-APRIL antibody. The company plans to share additional clinical data and development plans at an R&D Spotlight in late summer. This comes as Climb Bio advances its lead program budoprutug through multiple indications with a runway into 2027. CLYM116 targets IgAN with an IND/CTA planned for the second half of 2025.

Implication

Investors should note that the initial safety data de-risks CLYM116 ahead of the 2H25 IND/CTA. However, the data are early and from a small Phase 1, so efficacy remains unproven. The positive readout is consistent with the existing BUY stance, but does not materially alter the risk/reward. Key catalysts remain the Phase 2 pMN initiation and SC budoprutug data. The runway through 2027 provides sufficient time to deliver these inflection points.

Thesis delta

The thesis remains largely unchanged. The initial CLYM116 safety data provides incremental validation, but the core thesis hinges on budoprutug and CLYM116's later-stage data. No material shift in stance.